 | |
| Clinical data | |
|---|---|
| Other names | RG7314 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C22H24ClN5O |
| Molar mass | 409.92 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Balovaptan (INNTooltip International Nonproprietary Name; developmental code nameRG7314), is aselectivesmall moleculeantagonist of thevasopressin V1A receptor which is under development byRoche for the treatment ofpost-traumatic stress disorder (PTSD).[1]
It was in aphase III clinical trial for adults and a phase II clinical trial for children for post-traumatic stress disorder.[2]
In January 2018, Roche announced that the USFood and Drug Administration (FDA) had grantedbreakthrough therapy designation for balovaptan in people with autism spectrum disorder (ASD).[3] The FDA granted this based on the results of the adult phase II clinical trial called VANILLA (Vasopressin ANtagonist to Improve sociaL communication in Autism) study.[4]
The phase III study concluded that balovaptan did not improve social communication in autistic adults.[5]
It was also in phase II studies for the treatment ofstroke. However, it has since been discontinued for both of those indications.[6]
